Please login to the form below
olipudase alfa
This page shows the latest olipudase alfa news and features for those working in and with pharma, biotech and healthcare.
Sanofi’s rare disease drug olipudase alfa scores in late-stage study
Olipudase alfa is designed to replace the enzyme that is deficient in the inherited disease, also known as Neimann-Pick disease. ... Both of these findings are consistent across the clinical studies with olipudase alfa.
Latest news
-
Sanofi rare disease drug a breakthrough, says FDA
The FDA gave the coveted status to olipudase alfa, which is designed to replace the enzyme that is deficient in the inherited disease, also known as acid sphingomyelinase deficiency (ASMD). ... Genzyme is developing olipudase alfa (GZ402665) for the type
More from news
Approximately 2 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
-
Pharmacovigilance Manager
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- Rare diseases: not so rare after all
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Virtual Patient Engagement Program: A Customer Story
- Putting Skin in the Game at AAD 2023
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- NHS England announces rare genetic disorder fast-tracking service
- NICE sees ‘promise’ in four UTI tests that could help in fight against AMR
- Connectome competitiveness
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Trust me, I’m from pharma
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Pfizer and Astellas’ Xtandi shows promise in phase 3 prostate cancer study
- Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
PMHub
Accession
Accession was a born from a passion and a vision. A passion to harness the power of market access to...
Latest intelligence
- Virtual Patient Engagement Program: A Customer Story
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Humancomms for humancare?
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- Rare diseases: not so rare after all
- The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
